Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Open access
Lockman, Shahin, Brummel, Sean S, Ziemba, Lauren, Stranix-Chibanda, Lynda, McCarthy, Katie, Coletti, Anne, Jean-Philippe, Patrick, Johnston, Ben, Krotje, Chelsea, Fairlie, Lee, Hoffman, Risa M, Sax, Paul E, Moyo, Sikhulile, Chakhtoura, Nahida, Stringer, Jeffrey SA, Masheto, Gaerolwe, Korutaro, Violet, Cassim, Haseena, Mmbaga, Blandina T, João, Esau, Hanley, Sherika, Purdue, Lynette, Holmes, Lewis B, Momper, Jeremiah D, Shapiro, Roger L, Thoofer, Navdeep K, Rooney, James F, Frenkel, Lisa M, Amico, K Rivet, Chinula, Lameck, Currier, Judith, Best, Brookie M., Blanchette, Cheryl, Browning, Renee, Cheng, Yao, Fox, Andee, Jaliaah, Nagawa, Knowles, Kevin, Mirochnick, Mark, Murtaugh, William A., Patras, Emmanuel, Pinilla, Mauricio, van Wyk, Jean, Whalen, Frances·2021·The Lancet

Abstract

SUMMARY Background: We compared the safety and efficacy of three antiretroviral regimens started in pregnancy: dolutegravir (DTG)+emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF); DTG+FTC/tenofovir disoproxil fumarate (TDF); and efavirenz (EFV)/FTC/TDF. Methods: Women with HIV-1 infection at 22 sites in 9 countries were randomized 1:1:1 at 14–28 weeks’ gestation to start each regimen (open-label). The primary efficacy outcome was virologic non-inferiority at delivery (−10% margin) of the combined DTG groups versus the EFV group, with superiority tested in a pre-planned secondary analysis. Primary safety outcomes, compared pairwise among treatment groups, were occurrence of any adverse pregnancy outcome (preterm delivery, small for gestational age, stillbirth, or spontaneous abortion) and occurrence of maternal and infant adverse events, grade ≥3. Primary analyses were intention-to-treat (ITT). Findings: We enrolled 643 women: 217 DTG+FTC/TAF, 215 DTG+FTC/TDF, 211 EFV/FTC/TDF. Enrollment medians were 22 weeks’ gestation, HIV-1 RNA 903 copies/mL (28% <200 copies/mL), and CD4 count 466 cells/uL. Delivery HIV-1 RNA was available for 605 (94%) women: 395 (98%) in the combined DTG groups had delivery HIV-1 RNA <200 copies/mL vs. 182 (91%) in the EFV group (difference 7% [95%CI 2%, 11%]; p=0·005). Fewer women assigned to DTG+FTC/TAF (24%) experienced the composite adverse pregnancy outcome than women assigned to either DTG+FTC/TDF (33%, difference −9% [95% CI −17%, −0·3%]; p=0·043) or EFV/FTC/TDF (33%, difference −9% [95%CI −17%, −0·1%]; p=0·047). Grade ≥3 maternal and infant adverse events did not differ by group. Preterm delivery was significantly lower with DTG+FTC/TAF (6%) than EFV/FTC/TDF (12%, difference −6% [95%CI −12%, −0·9%]; p-value = 0·023). Stillbirth was more frequent with DTG (non-significant, p=0.064). Neonatal mortality was more frequent with EFV/FTC/TDF (5%) than DTG+FTC/TAF (1·0%, p=0·019) or DTG+FTC/TDF (1·5%, p=0·050). Interpretation: When started in pregnancy, DTG-containing regimens had superior virologic efficacy at delivery compared with EFV/FTC/TDF. DTG+FTC/TAF had the lowest frequency of the composite adverse pregnancy outcome and of neonatal death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00314-7

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 164

Metadata

Authors
Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., Jean-Philippe, P., Johnston, B., Krotje, C., Fairlie, L., Hoffman, R. M., Sax, P. E., Moyo, S., Chakhtoura, N., Stringer, J. S., Masheto, G., Korutaro, V., Cassim, H., Mmbaga, B. T., João, E., Hanley, S., Purdue, L., Holmes, L. B., Momper, J. D., Shapiro, R. L., Thoofer, N. K., Rooney, J. F., Frenkel, L. M., Amico, K. R., Chinula, L., Currier, J., Best, B. M., Blanchette, C., Browning, R., Cheng, Y., Fox, A., Jaliaah, N., Knowles, K., Mirochnick, M., Murtaugh, W. A., Patras, E., Pinilla, M., van Wyk, J., & Whalen, F.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-04
Volume
397
Issue
10281
Pages
1276-1292
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3142355365
Cited by
164
References
4
FWCI
9.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00314-7
The paper
Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., Jean-Philippe, P., Johnston, B., Krotje, C., Fairlie, L., Hoffman, R. M., Sax, P. E., Moyo, S., Chakhtoura, N., Stringer, J. S., Masheto, G., Korutaro, V., Cassim, H., Mmbaga, B. T., . . . Whalen, F. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)00314-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.